Organogenesis Expands into China

shanghai.pngOrganogenesis, one of the pioneering tissue engineering companies, is partnering with China’s National Tissue Engineering Center (NTEC) to bring Organogenesis’ regenerative therapies to the Chinese marketplace. NTEC is a Shanghai-based private company that is funded by the Chinese government, and it was launched by a Harvard/MIT-trained plastic surgeon, Dr. Yiling Cao. The two companies look to have a three-phase agreement in place that starts with Organogenesis exporting it’s tissue products into China for distribution by NTEC. If certain milestones are met (likely based on sales and successful deployment of the living tissue product to patients), phase II would see the transfer of manufacturing to NTEC for distribution throughout Asia. Phase III would include joint development of new products, which Organogenesis would retain certain regional rights to outside of Asia.


This is the first move by a major regenerative medicine player into Asia, although Theravitae started in Thailand due to the ease of the local regulatory processes. There is most definitely a market for regenerative therapies in Asia due to the huge population and problems with smoking, but there is also tremendous business risk associated with the region. The business risks stem from several factors including intellectual property, government involvement in the businesses, and lack of financial infrastructure (among others). Organogenesis must see this move as a strategic way to establish manufacturing within the Pacific Rim, and Shanghai is an ideal hub for quickly getting their short shelf-life products distributed throughout Asia.

Organogenesis has built a profitable business here in the US, and it is possible they believe that the manufacturing process is sufficiently robust to transfer to another country. If this is true, they may be able to leverage some of the cost-cutting strategies that comes with moving to China, and if they can maintain a high quality product and extend the shelf life of their living engineered tissues, then one could predict that all of Organogensis’ manufacturing could eventually be centralized in China, creating long term competitive advantages. I am sure that scenario is a long way off, but I also bet that many of Organogenesis’ regenerative medicine peers will be watching closely to see what develops out of this partnership on the other side of the world.


About jrowley

This blog is about the technology behind Regenerative Medicine - including, but not limited to, stem cells therapies, biomaterial-based devices, as well as tissue engineered products. My name is Jon Rowley. I have been in the Regenerative Medicine field since 1994 (undergraduate research), and have my PhD in Biomedical Engineering from the University of Michigan in Biomedical Engineering. I am currently an employee of Aastrom Biosciences, an adult autologous cell therapy company. You can see my professional creds at: Important Note: Absolutely everything posted in this blog is my personal opinion and is in no way the opinion of my employer, Aastrom Biosciences, or approved by anyone before it is posted. No warranties or other guarantees will be offered as to the quality of the opinions or anything else offered here.
This entry was posted in Bioprocessing, business models, Joint Ventures, Manufacturing, Regenerative Medicine and tagged , , , , . Bookmark the permalink.

1 Response to Organogenesis Expands into China

  1. Pingback: China and the Regenerative Medicine Industry « The Regeneration Station

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s